EMVC Stock Overview A venture capital firm specializing in seed, growth capital, early and mid stage investments. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteEMV Capital plc Competitors Price History & Performance
Summary of share price highs, lows and changes for EMV Capital Historical stock prices Current Share Price UK£0.55 52 Week High UK£0.81 52 Week Low UK£0.43 Beta 1.65 1 Month Change 11.22% 3 Month Change 6.86% 1 Year Change -6.03% 3 Year Change -34.34% 5 Year Change 14.74% Change since IPO -96.70%
Recent News & Updates EMV Capital plc has filed a Follow-on Equity Offering. Dec 31
EMV Capital plc has completed a Follow-on Equity Offering in the amount of £1.5 million. Dec 05
New minor risk - Share price stability Dec 03 EMV Capital plc has filed a Follow-on Equity Offering in the amount of £1.5 million. Dec 03
First half 2024 earnings released: UK£0.071 loss per share (vs UK£0.058 loss in 1H 2023) Oct 03
New minor risk - Shareholder dilution Aug 07 See more updates EMV Capital plc has filed a Follow-on Equity Offering. Dec 31
EMV Capital plc has completed a Follow-on Equity Offering in the amount of £1.5 million. Dec 05
New minor risk - Share price stability Dec 03 EMV Capital plc has filed a Follow-on Equity Offering in the amount of £1.5 million. Dec 03
First half 2024 earnings released: UK£0.071 loss per share (vs UK£0.058 loss in 1H 2023) Oct 03
New minor risk - Shareholder dilution Aug 07
New major risk - Revenue and earnings growth Jul 08
Shareholders Will Probably Hold Off On Increasing NetScientific plc's (LON:NSCI) CEO Compensation For The Time Being Jul 03
New minor risk - Shareholder dilution Jun 24
NetScientific plc, Annual General Meeting, Jul 10, 2024 Jun 19
Full year 2023 earnings released: UK£0.11 loss per share (vs UK£0.14 loss in FY 2022) Jun 15
NetScientific plc to Report Fiscal Year 2023 Results on Jun 13, 2024 May 31
New minor risk - Financial data availability Apr 15
New minor risk - Shareholder dilution Feb 06
Pds Biotech Announces Updated Survival Data from Nci-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients Nov 11
Would NetScientific (LON:NSCI) Be Better Off With Less Debt? Nov 03
First half 2023 earnings released: UK£0.058 loss per share (vs UK£0.066 loss in 1H 2022) Oct 02
NetScientific plc, Annual General Meeting, Jun 29, 2023 Jun 06
Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.13 loss in FY 2021) Jun 01
NetScientific plc Announces Board Changes May 31
Netscientific plc Announces Board Changes Feb 02
NetScientific plc Announces the Completion of Enrolment in the First Stage of the Checkpoint Inhibitor Refractory Group of Its Versatile-002 Phase 2 Study for the Potential Treatment of Recurrent And/Or Metastatic Human Papillomavirus (Hpv16)-Positive Head and Neck Cancer Dec 17
NetScientific plc Announces Board Changes Dec 13
No independent directors Nov 16
NetScientific plc Announces Board Changes Nov 09
Full year 2021 earnings: EPS and revenues miss analyst expectations Sep 30
Price target increased to UK£2.00 Sep 30
NetScientific plc (AIM:NSCI) completed the acquisition of 30% stake in Vortex Biotech Holdings Ltd. Aug 17
NetScientific plc has completed a Follow-on Equity Offering in the amount of £1.499996 million. Jun 23
NetScientific plc, Annual General Meeting, Jun 29, 2022 Jun 09
NetScientific plc, Annual General Meeting, Jun 29, 2022 Jun 08
Full year 2021 earnings: EPS and revenues miss analyst expectations May 13
NetScientific plc to Report Fiscal Year 2021 Results on May 12, 2022 May 09
NetScientific plc (AIM:NSCI) entered into a agreement to acquire 30% stake in Vortex Biotech Holdings Ltd for £0.3 million. May 08
No independent directors Apr 27
NetScientific plc (AIM:NSCI) acquired 75% stake in Cetromed Limited from Zahra Holdings Limited for £0.19 million. Dec 22
First half 2021 earnings released: UK£0.079 loss per share (vs UK£0.11 loss in 1H 2020) Oct 01
NetScientific plc has completed a Follow-on Equity Offering in the amount of £7.74556 million. Jun 11
Full year 2020 earnings released: UK£0.11 loss per share (vs UK£0.40 loss in FY 2019) Apr 20
Full year 2020 earnings released: UK£0.029 loss per share (vs UK£0.40 loss in FY 2019) Apr 02
NetScientific plc (LON:NSCI) Insiders Increased Their Holdings Feb 18 NetScientific plc Confirms Appointment of Stephen Crowe as Chief Financial Officer
NetScientific plc (AIM:NSCI) agreed to acquire remaining 43.6% stake in ProAxsis Ltd from Qubis Limited and the founders (sellers) for £0.23 million. Oct 18 NetScientific plc (AIM:NSCI) completed the acquisition of EMV Capital Ltd from Futura Messis Group Ltd.
NetScientific plc has completed a Follow-on Equity Offering in the amount of £2.299996 million. Aug 06
An unknown buyer acquire 9.55% minority stake in NetScientific plc (AIM:NSCI) from Acacia Research Corporation (NasdaqGS:ACTG). Jul 30 Shareholder Returns EMVC GB Medical Equipment GB Market 7D 0% 5.4% 3.3% 1Y -6.0% -6.0% 10.6%
See full shareholder returns
Return vs Market: EMVC underperformed the UK Market which returned 10.6% over the past year.
Price Volatility Is EMVC's price volatile compared to industry and market? EMVC volatility EMVC Average Weekly Movement 8.8% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.8% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: EMVC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: EMVC's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company EMV Capital plc is a venture capital firm specializing in seed, growth capital, early and mid stage investments. The firm focuses to invest in sustainability, life science, technology, transformative biomedical, deep tech, semiconductors, industrials, robotics, AI and healthcare technologies focusing on digital health, diagnostics, and therapeutics sectors. It also prefers to invest in companies that significantly improve the health and well-being of people with chronic diseases.
Show more EMV Capital plc Fundamentals Summary How do EMV Capital's earnings and revenue compare to its market cap? EMVC fundamental statistics Market cap UK£13.27m Earnings (TTM ) -UK£2.97m Revenue (TTM ) UK£1.81m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EMVC income statement (TTM ) Revenue UK£1.81m Cost of Revenue UK£374.00k Gross Profit UK£1.44m Other Expenses UK£4.41m Earnings -UK£2.97m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.12 Gross Margin 79.33% Net Profit Margin -164.23% Debt/Equity Ratio 6.1%
How did EMVC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/20 22:05 End of Day Share Price 2025/01/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources EMV Capital plc is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Maxim Jacobs Edison Investment Research Nicholas Keher Investec Bank plc (UK) Dr Julie Panmure Liberum
Show 3 more analysts